Body Composition and Radiation Dose in 177Lu-PSMA Therapy for Advanced Prostate Cancer
Studies how body fat and muscle affect radiation dose in 177Lu-PSMA therapy.
Key facts
- Who runs it
- Centre Henri Becquerel
- Where
- Rouen, FranceSee the site
- Trial code
- Registry title
- Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- Sept 2026
- Expected to end
- Jun 2029
- Type of study
- Interventional
- Treatments tested
- 177Lu-PSMA-617 + SPECT/CT dosimetry
- Record updated
- 14 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older with prostate cancer that has spread, who will get 177Lu-PSMA radioligand treatment and whose tumour shows PSMA on a PET/CT scan.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma confirmed by tissue examination. The study title and summary describe metastatic castration-resistant prostate cancer.
- Earlier treatment
- A team of doctors must have decided on 177Lu-PSMA treatment.
- Biomarker or test result
- PSMA shown in tumour lesions on a 68Ga-PSMA PET/CT scan.
Main reasons for not taking part
- Cannot understand the study or follow its rules (for example language barrier, psychological or geographic reasons)
- Under legal protection (tutelle, curatelle, sauvegarde de justice)
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Signed informed consent
- Male, age >= 18 years
- Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment
- PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET/CT
- Affiliated to or beneficiary of a social security scheme
Who cannot take part
- Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)
- Patient under legal protection (tutelle, curatelle, sauvegarde de justice)
Where in France
- Centre Henri BecquerelRouen, FranceContact: Pierre Decazes, MD, PhDNo longer taking part
About the trial
What the trial wants to find out
COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.
The group in the trial
- COCORIVOTreatment being tested
Patients with mCRPC treated with 177Lu-PSMA-617 undergoing additional SPECT/CT acquisitions and body composition analysis
Treatment: 177Lu-PSMA-617 + SPECT/CT dosimetry
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact de la Composition Corporelle Sur la dosimétrie de la radiothérapie Interne vectorisée au 177Lu-PSMA
- Plain-language title
- Body Composition and Radiation Dose in 177Lu-PSMA Therapy for Advanced Prostate CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 14 May 2026